Stock Ratings / Health Care / EDIT / earnings

PROK (44) ALLO (38) AUTL (25) RGNX (39) ⌘ Pro Terminal →

Editas Medicine Inc. (EDIT) Next Earnings Date & Expected ±12.5% Move

$2.93 -0.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Editas Medicine Inc. (EDIT) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $450.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EDIT)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.37 Expected Swing

MODEL EARNINGS SETUP GAUGE

EDIT Quantitative Pre-Earnings Setup: 37/100

Trailing EPS: $4.25 • YoY Revenue Growth: 25.4%

Model Bullish Setup (37/100)Model Risk Weight (63/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$40.5M	-$160.1M	-$165.8M	52%
FY 2024	2024-12-31	$32.3M	-$237.1M	-$219.1M	52%
FY 2023	2023-12-31	$78.1M	-$153.2M	-$132.2M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EDIT)

✓Walkthrough of EDIT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EDIT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.33%▼ DESCENDING CHANNEL

2026-10-30O $2.89H $2.93L $2.60C $2.93VOL 2.91M

RES: $3.14SUP: $2.18SMA50: $2.76SMA200: $2.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EDIT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EDIT Butterfly Map → + Track EDIT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +25.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EDIT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EDIT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EDIT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EDIT)

Health Care Rank #747 of 1016 ⚔️ PROK vs EDIT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EDIT vs. PROK, ALLO, AUTL, RGNX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Editas Medicine Inc. (EDIT) ranks #747 by composite RQD confidence (37/100, grade D-) and #466 by equity capitalization ($450.0M). Within this direct 5-issuer industry benchmark cohort, EDIT leads on earnings valuation at N/A trailing P/E, while EDIT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PROK currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with EDIT at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EDIT ACTIVE Editas Medicine Inc.	D-	37/100	—	—	-35.0%	-0.68%	$450.0M	Benchmark Subject
PROK ProKidney Corp. (Class A)	D	44/100	—	—	-35.0%	-3.29%	$444.4M	/prok-vs-edit →
ALLO Allogene Therapeutics Inc.	D-	38/100	—	—	-35.0%	-3.85%	$431.9M	/allo-vs-edit →
AUTL Autolus Therapeutics plc	E	25/100	—	-27.8%	-35.0%	-3.07%	$420.5M	/autl-vs-edit →
RGNX REGENXBIO Inc.	D-	39/100	—	—	-35.0%	+2.35%	$489.2M	/rgnx-vs-edit →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001650664

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Editas Medicine Inc. (EDIT) reported GAAP revenue of $40.5M (+25.4% vs. FY2024 revenue of $32.3M , and -48.1% cumulative change since FY2023) , GAAP net income of -$160.1M, operating cash flow of -$165.2M, and free cash flow of -$165.8M (+24.3% YoY). On the balance sheet, EDIT closed FY2025 with $186.5M in total assets against $53.6M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$40.5M	-$160.1M	-$165.2M	-$165.8M	$186.5M	$53.6M
FY2024 (FY)	2024-12-31	$32.3M	-$237.1M	-$210.3M	-$219.1M	$341.6M	$52.4M
FY2023 (FY)	2023-12-31	$78.1M	-$153.2M	-$132.2M	-$132.2M	—	—

3. EDIT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EDIT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Editas Medicine Inc. (NASDAQ: EDIT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.93 (-0.68% 1D, market cap $450.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EDIT ranks #747 in composite RQD confidence.

How does EDIT compare to PROK and ALLO in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EDIT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PROK (ProKidney Corp. (Class A)) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $444.4M) and ALLO (Allogene Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $431.9M). Among the 5-stock peer group, EDIT leads on earnings multiple (N/A) while EDIT leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EDIT?

Per EDIT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001650664), Editas Medicine Inc. generated $40.5M in revenue (+25.4% YoY), -$160.1M in net income, and -$165.8M in free cash flow against $186.5M in total assets and $53.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EDIT trading relative to its 50-day, 200-day, and 52-week technical levels?

EDIT last traded at $2.93 (-0.68% on volume of 3,226,724 shares), positioning the stock +6.16% above its 50-day simple moving average ($2.76) and +9.33% above its 200-day simple moving average ($2.68). Across its 52-week range of $1.66 to $3.94, EDIT sits at the 55.7% percentile with a 14-day RSI of 50.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.56 to $3.30).

EDIT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is EDIT's next earnings date?

Based on SEC filing cadence, Editas Medicine Inc. (EDIT)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is EDIT stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for EDIT, spanning a range between $2.56 and $3.3.

Direct Sub-Reports: EDIT RQD Cockpit EDIT 12M Forecast EDIT Earnings & Move EDIT Dividends & DRIP EDIT Insiders & 13F EDIT Whale Options EDIT Profit Sankey EDIT News & Why